Perspective on the current state of the LRRK2 field

Jean Marc Taymans, Matt Fell, Tim Greenamyre, Warren D. Hirst, Adamantios Mamais, Shalini Padmanabhan, Inga Peter, Hardy Rideout, Avner Thaler

Research output: Contribution to journalArticlepeer-review


Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field.

Original languageEnglish
Article number104
Journalnpj Parkinson's Disease
Issue number1
StatePublished - Dec 2023

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Perspective on the current state of the LRRK2 field'. Together they form a unique fingerprint.

Cite this